Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress

Figure 5

Phospho-aspirin-2 induces p53 activity and p21. A: PA-2 1 × IC50-3 × IC50 increased the DNA binding activity of p53 in MDA-MB-231 and BT-20 cells, as determined by electrophoretic mobility shift assay. B: PA-2 1.5 × IC50 disrupted the interaction between p53 and MDM2 in MDA-MB-231 and BT-20 cells. Following treatment with PA-2, p53 was immunoprecipitated and the levels of MDM2 were determined. C: Upper: PA-2 1.5 × IC50 induced the expression of p21 in MDA-MB-231 and BT-20 cells. Lower: PA-2 induced the expression of p21 in MDA-MB-231 xenografts (treatment protocol).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us